1. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Issue 1 (21st April 2020) Authors: Lopes, Jared E; Fisher, Jan L; Flick, Heather L; Wang, Chunhua; Sun, Lei; Ernstoff, Marc S; Alvarez, Juan C; Losey, Heather C Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗